Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. From Wikipedia
Presented at ASCO, the phase II study indicates that adding cetuximab to avelumab may offer a new treatment path for patients who progress after initial PD-1 therapy.
